POC(Point of Care) 혈액검사 제품 시장은 2025년에 198억 2,000만 달러로 평가되었습니다. 2026년에는 212억 9,000만 달러에 이르고, CAGR 8.24%로 성장을 지속하여 2032년까지 345억 1,000만 달러에 이를 것으로 예측되고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 198억 2,000만 달러 |
| 추정 연도 : 2026년 | 212억 9,000만 달러 |
| 예측 연도 : 2032년 | 345억 1,000만 달러 |
| CAGR(%) | 8.24% |
Point-of-Care 혈액검사는 임상 워크플로우를 빠르게 변화시키고, 기존 검사실을 넘어선 진단을 가능하게 하며, 다양한 의료현장에서 신속한 임상적 판단을 가능케 합니다. 본 보고서에서는 먼저 현황을 살펴보고, 기기의 소형화, 연결성, 규제 조화가 응급실에서 재택의료에 이르기까지 도입 장벽을 어떻게 낮춰왔는지를 중점적으로 설명합니다. 서론에서는 제조업체, 의료 시스템, 상환 이해관계자들에게 가장 중요한 기술과 이용 사례를 프레임워크로 제시하고, 후속 분석의 기초가 되는 핵심 용어와 장비 클래스를 명확히 합니다.
현장 혈액 검사 환경은 기술 혁신, 규제 진화, 의료 서비스 제공 모델의 변화로 인해 혁신적으로 변화하고 있습니다. 분자진단 및 면역 측정의 민감도 향상으로 침대 옆에서 안정적으로 측정할 수 있는 분석 대상 물질의 범위가 확대되었습니다. 한편, 전기화학 및 광학 센서 기술의 발전으로 검사 당 복잡성과 비용이 감소했습니다. 이러한 혁신을 통해 기존에는 중앙 검사실이 필요했던 질병에 대한 정확한 검사가 가능해져 임상적 판단의 신속성과 다양한 환경에서의 선별 및 치료의 실현을 촉진하고 있습니다.
2025년 미국의 관세 환경은 현장 진료 혈액 검사에 사용되는 특정 부품 및 완제품의 투입 비용을 증가시켜 제조업체와 유통업체가 조달 및 가격 전략을 재평가하도록 유도했습니다. 공급망 관리자는 수입 관세 위험을 줄이기 위해 공급업체 기반 다변화, 현지 재고 버퍼 강화, 핵심 부품의 니어쇼어링 추진을 가속화하는 등의 대응을 취했습니다. 이러한 업무상의 변화는 특히 특수 시약이나 정밀하게 설계된 센서 부품에 의존하는 기기에서 생산 리드 타임과 조달 복잡성에 측정 가능한 다운스트림 효과를 가져왔습니다.
세분화 분석을 통해 제품 유형, 최종 사용자, 용도, 기술, 시료 유형에 걸쳐 임상적 요구와 기술적 역량, 상업적 기회가 일치하는 영역을 파악할 수 있습니다. 제품 차원의 차별화는 혈액가스 분석, 심근 마커, 응고 검사, 혈당 모니터링, 헤모글로빈/혈액학, 감염 검사 등의 모달리티를 중심으로 전개됩니다. 응고 검사는 APTT 검사, D다이머 검사, PT INR 검사로 세분화되며, 감염 검사는 코로나19, 간염, HIV, 독감 등을 검사합니다. 진료 현장에서 여러 가지 보완적 검사를 수행할 수 있는 장치는 검체 처리 시간을 줄이고 진단 기간을 단축하여 명확한 임상적 유용성을 보장합니다. 최종 사용자는 외래진료센터, 진단검사실, 재택의료 환경, 병원, 진료소 등으로 다양하며, 각 환경마다 처리 능력과 검사 결과 보고 시간, 인력 배치, 비용 상환 문제 등 다양한 도입 요인이 존재합니다. 병원에서는 견고성과 통합성이 우선시되는 반면, 재택치료 환경에서는 사용 편의성과 연결성이 중요시됩니다.
지역별로 분석한 결과, 의료 인프라, 규제 프레임워크, 도입 경로의 차이에 따라 혈액검사 도입 형태가 달라지는 것으로 나타났습니다. 미국 대륙에서는 통합의료 네트워크와 입원기간 단축 및 만성질환 관리 개선을 평가하는 상환제도에 힘입어 급성기 의료와 1차의료 영역 모두에서 빠르게 도입이 진행되고 있습니다. 반면, 유럽, 중동, 아프리카은 상황이 복잡하여 일부 국가에서는 규제 조화가 진행되어 도입이 가속화되는 반면, 자원이 부족한 국가에서는 저비용의 강력한 플랫폼과 분산형 검사 전략에 대한 수요가 집중되고 있습니다. 또한, 아시아태평양에서는 대상 질환의 높은 유병률과 오지 및 도시화가 진행 중인 지역의 검사 접근성 확대를 위한 정부 정책을 배경으로 진단 능력 향상을 위한 민간 및 공공 투자가 빠르게 증가하고 있습니다.
현장 진료 혈액 검사 경쟁 환경은 기존 진단 기기 제조업체, 전문 기기 혁신 기업, 틈새 임상 적응증 획득을 목표로 하는 신생 기술 진출기업 등이 혼재된 형태로 형성되어 있습니다. 심층적인 임상 검증, 규제 대응 경험, 제조 규모를 겸비한 기업은 병원 및 검사실 채널에서 우위를 점하고 있습니다. 한편, 작고 민첩한 기업들은 사용자 인터페이스 설계, 시약 화학, 분자 검사의 소형화에서 자주 혁신을 추진하고 있습니다. 전략적 차별화는 소프트웨어, 연결성, 의사결정 지원 기능을 통해 기기를 임상 워크플로우에 통합하는 능력에 점점 더 의존하고 있으며, 이는 원시 데이터 분석 성능을 넘어 명확한 임상의사 가치를 제공합니다.
업계 리더는 제품 설계, 규제 대응, 채널 개발을 연계한 협력 전략을 추진하여 대상 의료 현장의 도입을 가속화해야 합니다. 모듈식 검사 확장이 가능한 플랫폼 접근을 우선적으로 고려하고, 응고 모니터링의 하위 유형이나 주요 감염병 검사 등 영향력 있는 검사로 초기 진입을 이룬 후, 동일한 하드웨어 생태계를 활용한 추가 분석 항목의 단계적 확대를 실현할 것입니다. 동시에 사용자 경험을 개선하고 연결 솔루션에 투자하여 임상 워크플로우 및 전자건강기록(EHR)과의 원활한 통합을 보장하고 임상의의 도입 장벽을 낮춰야 합니다.
본 조사는 질적 조사를 통한 1차 데이터 수집과 정량적 데이터 통합을 결합한 혼합 방식을 채택하여 확고한 근거에 기반한 지식을 확립하고자 하였습니다. 1차 조사에서는 임상의, 검사실 책임자, 조달 담당자, 규제 전문가를 대상으로 구조화된 인터뷰를 실시하여 의료 현장의 실제 운영상의 문제점과 도입 촉진요인을 파악했습니다. 2차 정보는 기술 동향, 규제 업데이트, 공중보건적 요인을 체계적으로 검토하여 1차 조사 결과와 삼각측량(트라이앵글레이션)을 통해 새로운 테마를 검증하였습니다.
기술 발전, 진화하는 의료 모델, 변화하는 규제 환경과 맞물려 환자 결과와 업무 효율성을 개선할 수 있는 구체적인 기회를 창출할 수 있는 전환점을 맞이하고 있는 현장 혈액검사 분야. 가장 성공적인 접근 방식은 엄격한 임상 검증과 사용자 중심 설계, 강력한 품질 시스템, 병원, 외래진료센터, 검사실, 재택의료 환경 등 각 현장의 고유한 요구를 충족시키는 유연한 상업적 모델을 결합하는 것입니다. 규제 대응과 공급망 복원력도 마찬가지로 중요하며, 특히 부품 조달과 가격 책정에 영향을 미치는 지정학적, 관세 관련 불확실성이 존재하는 상황에서는 그 중요성이 더욱 커집니다.
The Point of Care Blood Testing Product Market was valued at USD 19.82 billion in 2025 and is projected to grow to USD 21.29 billion in 2026, with a CAGR of 8.24%, reaching USD 34.51 billion by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 19.82 billion |
| Estimated Year [2026] | USD 21.29 billion |
| Forecast Year [2032] | USD 34.51 billion |
| CAGR (%) | 8.24% |
Point-of-care blood testing is rapidly reshaping clinical workflows, extending diagnostics beyond traditional laboratories and enabling faster clinical decision-making across diverse care settings. This report opens with an orientation to the current landscape, emphasizing how device miniaturization, connectivity, and regulatory harmonization have collectively reduced barriers to deployment in settings ranging from emergency departments to home-based care. The introduction frames the technologies and use cases that are most consequential for manufacturers, health systems, and reimbursement stakeholders, while clarifying core terminology and device classes that underpin subsequent analysis.
The narrative situates point-of-care blood testing within the broader trend toward decentralized and patient-centric care. It highlights how clinical priorities-such as reducing time to diagnosis for infectious diseases, optimizing anticoagulation management through coagulation monitoring, and enabling real-time glucose and cardiac marker measurement-drive procurement and adoption decisions. Furthermore, the introduction underscores the role of interoperability, quality assurance, and clinician training in determining how quickly and effectively point-of-care tools integrate into established clinical pathways, setting the stage for deeper examination of market dynamics and strategic implications in later sections.
The landscape for point-of-care blood testing is undergoing transformative shifts driven by technological innovation, regulatory evolution, and changing care delivery models. Advances in molecular diagnostics and immunoassay sensitivity have expanded the range of analytes that can be reliably measured at the bedside, while improvements in electrochemical and optical sensor technology have lowered per-test complexity and cost. These innovations enable accurate testing for conditions that previously required centralized laboratories, thereby accelerating clinical decision-making and enabling triage and treatment in diverse settings.
Concurrently, regulatory pathways in many jurisdictions are adapting to accommodate rapid diagnostic technologies, with a focus on post-market surveillance and quality controls that maintain clinical standards while reducing time to market. The shift toward value-based care and bundled payment models incentivizes shorter hospital stays and outpatient management, underscoring the need for point-of-care tests that deliver actionable results quickly. Integration with electronic health records and cloud-based analytics is enhancing data continuity and enabling remote monitoring, which supports chronic disease management and population health initiatives. Taken together, these shifts are redefining where diagnostics occur, who performs them, and how results inform both immediate and longitudinal clinical decisions.
The tariff environment in the United States in 2025 introduced elevated input costs for certain components and finished devices used in point-of-care blood testing, prompting manufacturers and distributors to reassess sourcing and pricing strategies. Supply chain managers responded by diversifying supplier bases, increasing local inventory buffers, and accelerating nearshoring initiatives for critical components to mitigate exposure to import duties. These operational shifts had measurable downstream effects on production lead times and procurement complexity, particularly for devices that rely on specialized reagents and precision-engineered sensor components.
In response, manufacturers prioritized design-for-manufacture approaches that reduced dependence on tariff-sensitive subsystems, while commercial teams adjusted contract structures to absorb or pass through additional costs in ways that preserved adoption momentum among health systems and ambulatory care providers. Strategic partnerships and long-term supply agreements emerged as mechanisms for stabilizing unit economics and minimizing price volatility. From a clinical standpoint, buyers emphasized total cost of ownership and reliability over headline device pricing, which influenced procurement decisions in hospitals, diagnostic laboratories, and decentralized care environments. These dynamics are likely to persist as stakeholders balance cost containment with the clinical imperative for rapid, reliable point-of-care testing.
Segmentation insights reveal where clinical needs align with technological capabilities and commercial opportunity across product types, end users, applications, technologies, and sample types. Product-level differentiation centers on modalities such as Blood Gas Analysis, Cardiac Markers, Coagulation Testing, Glucose Monitoring, Hemoglobin Hematology, and Infectious Disease Testing, with coagulation further subdivided into APTT testing, D dimer testing, and PT INR testing and infectious disease assays covering Covid-19, Hepatitis, HIV, and Influenza; devices that can perform multiple complementary assays at the point of care secure distinct clinical utility by reducing sample handling and accelerating decision timelines. End users span Ambulatory Care Centers, Diagnostic Laboratories, Home Care Settings, Hospitals, and Physicians Offices, each exhibiting different adoption drivers ranging from throughput and turnaround time to staffing and reimbursement concerns; hospitals prioritize robustness and integration, while home care settings emphasize ease of use and connectivity.
Applications cluster around Cardiac Monitoring, Coagulation Monitoring, Critical Care, Diabetes Monitoring, and Infectious Disease Diagnosis, with the highest clinical urgency found where rapid intervention changes patient outcomes. Technologies such as Electrochemical sensors, Immunoassay platforms, Molecular Diagnostics, and Optical detection shape assay sensitivity, specificity, and portability, and therefore influence which applications can realistically migrate to the point of care. Sample type considerations-Capillary Blood, Plasma, Serum, Venous Blood, and Whole Blood-determine pre-analytical workflows and user training requirements; capillary and whole blood testing favor decentralized use but require rigorous quality assurance to ensure clinical concordance with laboratory standards. Cross-segmentation analysis highlights that successful offerings combine an appropriate technology for the intended analyte, a user-centric interface for the target end user, and validated workflows for the chosen sample type to achieve adoption at scale.
Regional insights reflect differing healthcare infrastructures, regulatory frameworks, and adoption pathways that shape how point-of-care blood testing is deployed. The Americas continue to emphasize rapid adoption in both acute care and primary care settings, supported by integrated health networks and reimbursement mechanisms that reward reduced length of stay and improved chronic disease management. In contrast, Europe, Middle East & Africa present a heterogeneous picture where regulatory harmonization in some countries accelerates adoption while resource constraints in others concentrate demand for low-cost, ruggedized platforms and decentralized testing strategies. Meanwhile, Asia-Pacific demonstrates strong growth in private and public investments for diagnostic capacity, driven by high prevalence of target conditions and government initiatives to expand access to testing in remote and urbanizing populations.
Across regions, differences in supply chain configurations and local manufacturing capabilities influence procurement timelines and pricing. Interoperability expectations and digital health infrastructure maturity also vary, which affects the extent to which data integration and remote monitoring features are realized. Stakeholders operating across these geographies must therefore tailor go-to-market approaches to align with local reimbursement models, regulatory requirements, and clinical practice patterns while leveraging scalable technology architectures that accommodate regional customization and global quality standards.
Competitive dynamics in point-of-care blood testing are shaped by a mix of established diagnostic manufacturers, specialist device innovators, and emerging technology entrants seeking to capture niche clinical indications. Companies that combine deep clinical validation, regulatory experience, and manufacturing scale maintain advantages in hospital and laboratory channels, while smaller, agile firms frequently drive innovation in user interface design, reagent chemistry, and molecular assay miniaturization. Strategic differentiation increasingly rests on the ability to integrate devices into clinical workflows through software, connectivity, and decision-support features that deliver clear clinician value beyond raw analytical performance.
Partnerships and alliances between device makers, reagent suppliers, and software developers are becoming more prevalent as firms seek to offer turnkey solutions that address the full testing pathway from sample collection to result interpretation and data management. Intellectual property around sensor technology and assay chemistries remains a critical barrier to entry for late-stage analytes, while nimble companies with strong reimbursement strategies and targeted clinical evidence can capture early-adopter segments. Additionally, manufacturers with robust post-market surveillance and quality systems secure trust among institutional buyers, who increasingly demand longitudinal performance data and clear lifecycle management plans for point-of-care platforms.
Industry leaders should pursue a coordinated strategy that aligns product design, regulatory engagement, and channel development to accelerate adoption across targeted care settings. Prioritize platform approaches that enable modular assay expansion, permitting an initial commercial entry with high-impact tests-such as coagulation monitoring subtypes or key infectious disease assays-followed by a staged rollout of additional analytes that leverage the same hardware ecosystem. Simultaneously, invest in user experience refinements and connectivity solutions to ensure seamless integration into clinical workflows and electronic health records, thereby reducing barriers to clinician adoption.
Operationally, diversify supply chains and consider nearshoring critical component production to mitigate tariff exposure and reduce lead-time volatility. Strengthen partnerships with clinical networks and key opinion leaders to generate pragmatic, peer-reviewed evidence that demonstrates real-world clinical utility and cost-effectiveness. Finally, tailor market entry strategies to specific end users by aligning pricing and support models with the procurement realities of hospitals, ambulatory centers, diagnostic laboratories, and home care providers, and ensure training and quality control resources are available to sustain long-term utilization and trust.
This research employed a mixed-methods approach that combined primary qualitative engagement with quantitative data synthesis to ensure robust, evidence-based findings. Primary research included structured interviews with clinicians, laboratory directors, procurement leads, and regulatory experts to capture real-world operational challenges and adoption drivers across care settings. Secondary sources were systematically reviewed to contextualize technological trends, regulatory updates, and public health drivers, and were triangulated with primary inputs to validate emerging themes.
Analytical methods encompassed cross-segmentation mapping to align product attributes with end-user needs, scenario analysis to assess impacts of policy and tariff changes on sourcing strategies, and technology readiness assessments that evaluated assay performance, manufacturability, and integration potential. Data quality was reinforced through respondent verification, expert panel reviews, and iterative synthesis to ensure that conclusions reflect both empirical evidence and practical stakeholder perspectives. Ethical considerations and data governance standards guided the treatment of proprietary inputs and ensured that analytical outputs remain actionable for commercial and clinical decision-makers.
Point-of-care blood testing stands at an inflection point where converging technological advances, evolving care models, and shifting regulatory landscapes create tangible opportunities to improve patient outcomes and operational efficiency. The most successful initiatives will be those that marry rigorous clinical validation with user-centric design, robust quality systems, and flexible commercial models that address the distinct needs of hospitals, ambulatory centers, laboratories, and home care settings. Regulatory navigation and supply chain resilience are equally critical, particularly in the context of geopolitical and tariff-driven uncertainties that affect component sourcing and pricing.
As stakeholders evaluate investment and partnership opportunities, they should prioritize solutions that demonstrate clear clinical utility, interoperability, and total cost implications within real-world care pathways. By focusing on modular platforms, targeted assay portfolios, and scalable distribution strategies, manufacturers and health systems can accelerate deployment while maintaining the quality and reliability that clinicians expect. The cumulative effect will be a more distributed diagnostic ecosystem that supports faster clinical decisions, better chronic disease management, and more resilient healthcare delivery models.